Researchers searching for buy PNC-27 online should evaluate PNC-27 as a research-use-only laboratory material, not a consumer product. For laboratory buyers, the key considerations are compound identity, purity documentation, batch-specific COAs, lot traceability, product labeling, storage information, and supplier evaluation. This guide explains how to evaluate PNC-27 30mg for controlled research procurement through Pure Lab Peptides while keeping published literature, product documentation, and RUO boundaries separate.
Fast Answer: Buy PNC-27 Online for Laboratory Research
Researchers can buy PNC-27 online for laboratory research by reviewing RUO labeling, batch-specific COA documentation, purity data, identity information, storage guidance, and supplier transparency before selecting a source. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption.
What Does “Buy PNC-27 Online” Mean in a Research Context?
The phrase “buy PNC-27 online” is addressed here as laboratory research procurement intent, not personal-use intent. In a compliant RUO context, the search is about whether qualified researchers, laboratory buyers, research institutions, and technical procurement teams can evaluate a PNC-27 research material with appropriate supplier documentation.
That evaluation should focus on the documentation chain: RUO labeling, product identity, batch-specific PNC-27 COA availability, purity data, identity testing, lot number matching, storage and handling information, and supplier language. FDA guidance on RUO labeling for in vitro diagnostic products is not a peptide purchasing rulebook, but it is useful as a general reminder that research-only labeling is intended to separate research materials from diagnostic or clinical use claims [1].
For technical procurement teams, “buy PNC-27 online for laboratory research” should therefore mean documenting what the material is, how the supplier presents it, what analytical evidence is available, and whether the product page avoids personal-use, treatment, dosing, or administration claims. Analytical guidance documents such as ICH Q2(R2) and ICH Q14 also reinforce the importance of validated analytical procedures, method development, and fit-for-purpose evaluation when analytical data are used to support quality review [2] [3].
PNC-27 Research Material Overview
PNC-27 is discussed in published literature as a chimeric p53-penetratin peptide. The literature describes it as a peptide containing a p53-derived HDM-2-binding region connected with a cell-penetrating peptide sequence, and reports generally characterize it in oncology-adjacent cellular model research rather than as a consumer product [4]. UniProt identifies TP53 as the human cellular tumor antigen p53 and MDM2 as an E3 ubiquitin-protein ligase, which provides neutral database context for the protein names commonly cited in PNC-27 papers [5] [6].
Structural literature on the p53-MDM2 interface has examined the MDM2 oncoprotein bound to a p53 transactivation-domain peptide, providing a structural research backdrop for papers that discuss p53-derived peptide motifs [7]. PNC-27 literature further reports computational, structural, in vitro, ex vivo, and preclinical model work involving membrane-associated HDM-2, cell-line systems, and pore-formation hypotheses [8].
For RUO procurement, the important point is not to convert that literature into product-use guidance. PNC-27 research-use-only positioning should be evaluated through identity, purity, analytical method, lot traceability, and supplier documentation. Published research context helps laboratories understand how the compound is discussed scientifically, but it does not establish instructions for use of an RUO material.
Why Researchers Search “Buy PNC-27 Online”
Researchers search this phrase because online procurement workflows often begin with product availability and documentation review. A laboratory buyer may want to confirm that a supplier lists PNC-27 30mg as a lyophilized powder, provides a batch-specific COA, states a clear purity claim, and maintains RUO labeling. The search should also help teams determine whether the supplier avoids language that would blur the line between research procurement and personal-use marketing.
Before a team decides to buy PNC-27, the procurement record should show that the product name, lot number, COA, storage documentation, and product form were reviewed together. HPLC is widely used in peptide analysis and purification, while LC-MS and mass spectrometry are commonly discussed in synthetic peptide characterization and impurity review [9] [10]. This is why PNC-27 purity documentation and PNC-27 identity testing should be considered together, not treated as interchangeable.
Research Procurement Checklist for PNC-27
- Verify that PNC-27 is labeled for research use only.
- Review the batch-specific certificate of analysis before procurement.
- Confirm that the COA includes purity documentation and identity information.
- Check whether HPLC, LC-MS, mass spectrometry, or another analytical method is listed.
- Compare the product name, lot number, and documentation for consistency.
- Assess whether the supplier avoids dosing, injection, therapeutic, diagnostic, personal-use, or animal-use claims.
- Document storage and handling information in laboratory records.
- Evaluate whether lyophilized powder form matches the needs of the research workflow.
- Confirm that the product is not marketed for human or animal consumption.
- Record supplier documentation, shipping information, and internal procurement approval in the laboratory file.
PNC-27 Quality Signals to Review Before Buying Online
Researchers evaluating where to buy PNC-27 online for laboratory research should prioritize quality signals that are visible, documentable, and lot-specific. General claims are less useful than records that connect the listed compound to a specific batch, analytical method, and supplier documentation package. USP General Chapter <621> provides general chromatography procedures, definitions, and system suitability concepts that help explain why chromatographic information can be relevant to material review [11].
| Evaluation Area | What Researchers Should Review | Why It Matters for RUO Procurement |
| RUO labeling | Confirm the product is clearly labeled for research use only | Helps separate research procurement from human-use positioning |
| COA availability | Review batch-specific certificate of analysis | Supports lot-level documentation and quality review |
| Purity data | Look for analytical support for the stated purity | Helps evaluate material consistency |
| Identity testing | Review HPLC, LC-MS, mass spectrometry, or related identity data where available | Helps confirm the material matches the listed compound |
| Lot traceability | Match lot numbers across product and documentation | Supports research recordkeeping |
| Product form | Confirm whether the material is supplied as lyophilized powder or another documented form | Supports laboratory planning |
| Storage information | Review storage and handling documentation | Helps maintain material integrity in laboratory settings |
| Supplier language | Confirm the supplier avoids dosing, therapeutic, or personal-use claims | Supports research-use-only positioning |
COA, Purity, and Identity Documentation
A PNC-27 COA should be reviewed as a batch-specific record, not as a generic marketing asset. Researchers should look for the compound name, lot number, test date, purity percentage, testing method, identity confirmation, molecular weight information where relevant, sequence information where relevant, chromatogram or mass data where available, product form, and storage documentation.
A purity percentage alone does not establish complete compound identity; researchers should evaluate purity, identity, method, lot number, and documentation together. In peptide characterization, mass spectrometry is frequently used to support identity and impurity analysis, while chromatographic methods can support separation and purity review [12] [13]. ICH Q2(R2) frames analytical validation around characteristics such as specificity, accuracy, precision, and range, while ICH Q14 discusses science- and risk-based analytical procedure development [2] [3].
flowchart TD
A[Receive product and COA] --> B{RUO labeling present?}
B -- No --> C[Flag procurement gap]
B -- Yes --> D{Lot number matches across label and COA?}
D -- No --> E[Request batch-specific documentation]
D -- Yes --> F{Identity supported by analytical method?}
F -- No --> G[Request HPLC, LC-MS, or equivalent]
F -- Yes --> H[Proceed to laboratory documentation and storage]
This workflow is intended for documentation review only. It does not describe preparation, administration, dosing, animal work, clinical work, or personal use. Laboratory teams should maintain procurement records that link the PNC-27 research material to the reviewed COA and internal research file.
Research Literature Context
Published PNC-27 literature is oncology-adjacent and should be handled with careful claim boundaries. The compound appears in papers examining p53-derived peptide design, HDM-2 interaction models, cell-line experiments, ex vivo systems, preclinical models, and analytical or imaging-related constructs [4] [8]. Cell-penetrating peptide literature provides additional class context for penetratin-related sequences, but CPP literature should not be treated as instructions for RUO product use [14].
Several PNC-27 papers discuss membrane-associated HDM-2, intact peptide behavior, leukemia cell-line models, ovarian ex vivo models, combination-model experiments, and nanoparticle conjugation research [15] [16] [17] [18] [19]. More recent papers and reviews discuss pore-formation models and membrane or mitochondrial observations in research systems [20] [21] [22] [23].
Those publications do not make an RUO product suitable for personal, clinical, diagnostic, therapeutic, veterinary, or consumer use. Published clinical literature should not be interpreted as use guidance for RUO materials. Oncology-adjacent or senescence-related literature must not be presented as therapeutic guidance or product-use claims.
Evidence Landscape
| Research Area | What Literature Examines | Evidence Type | RUO Interpretation |
| Compound identity | Molecular structure, peptide classification, p53-derived sequence context, or HDM-2-related terminology | Database / analytical / structural literature | Supports identification, not product-use claims |
| Pathway or category context | Oncology-adjacent cell-model research involving p53-derived peptide and HDM-2 discussion | Review / in vitro / ex vivo / preclinical | Useful for research context, not therapeutic claims |
| Analytical testing | Purity, identity, and batch verification | HPLC / LC-MS / mass spectrometry / COA | Supports documentation review |
| Storage and stability | Material form and handling considerations | Laboratory documentation | Supports research workflow planning |
Claim Boundary Table
| Research-Safe Statement | Why It Is Acceptable | Non-Compliant Version to Avoid |
| “PNC-27 is discussed in published research related to oncology-adjacent cellular model literature.” | Describes literature context without making a product claim | “PNC-27 helps with a human disease outcome.” |
| “Researchers should review COA and identity data before procurement.” | Focuses on documentation and quality review | “Users should buy PNC-27 for results.” |
| “Pure Lab Peptides supplies PNC-27 as a research-use-only material.” | Clarifies intended use | “Pure Lab Peptides supplies PNC-27 for therapy.” |
| “The phrase buy PNC-27 online is addressed as research procurement intent.” | Qualifies commercial search intent | “Buy PNC-27 online for personal use.” |
| “PNC-27 supplier documentation should be evaluated at the lot level.” | Connects procurement to traceability and records | “Supplier claims can replace analytical documentation.” |
How Pure Lab Peptides Presents PNC-27
Pure Lab Peptides presents PNC-27 30mg as a research-use-only material. The product is supplied as lyophilized powder, carries a ≥99% purity claim, and has batch-specific COA documentation available. Researchers should review the Pure Lab Peptides PNC-27 research-use-only product page for RUO labeling, product details, purity information, and batch-specific documentation.
For procurement review, PNC-27 research-use-only documentation should include product page details, the batch-specific COA, storage and handling documentation, lot-level traceability, and supplier transparency. Researchers comparing PNC-27 research material suppliers should also confirm that product language stays within research procurement and does not present dosing, personal-use, animal-use, diagnostic, clinical, or therapeutic guidance.
Common Misunderstandings About Buying PNC-27 Online
Misunderstanding: “Buy PNC-27 online” means personal use
Buy PNC-27 online should not be interpreted as personal-use guidance on this page. The phrase is addressed as laboratory procurement intent for qualified researchers reviewing RUO labeling, documentation, purity data, identity information, lot traceability, and supplier transparency.
Misunderstanding: Published literature equals product-use guidance
Published PNC-27 literature describes research models, structural hypotheses, and experimental systems. It does not provide instructions for using an RUO product. Research literature related to cellular pathways should not be converted into product-use claims for RUO materials.
Misunderstanding: Purity percentage alone proves identity
PNC-27 purity documentation is important, but purity percentage alone is not complete identity documentation. Researchers should review purity, identity testing, method information, lot number, product name consistency, and any chromatogram or mass data together before completing procurement records.
Misunderstanding: COA documentation does not need to be batch-specific
A general quality statement is not the same as a batch-specific PNC-27 COA. Lot-level documentation helps laboratories connect the received research material to the analytical record, product label, internal purchase record, and storage file.
Misunderstanding: RUO labeling supports human or animal use
RUO labeling does not support human use, animal use, clinical use, diagnostic use, veterinary use, or consumer use. It helps define the material as a laboratory research compound and should be supported by supplier language that avoids personal-use and treatment positioning.
Misunderstanding: Supplier claims can replace analytical documentation
Supplier transparency is useful only when it is supported by reviewable records. PNC-27 supplier documentation should include batch-specific COA access, identity information, purity documentation, storage information, lot traceability, and product-form details.
FAQs About Buying PNC-27 Online for Research
Where can researchers buy PNC-27 online for laboratory research?
Researchers can buy PNC-27 online for laboratory research from an RUO supplier that provides clear labeling, batch-specific COA access, purity documentation, identity information, storage guidance, and lot traceability. Pure Lab Peptides lists PNC-27 30mg for research-use-only procurement with product documentation available for review.
What should researchers check before buying PNC-27 online?
Before buying PNC-27 online, researchers should check RUO labeling, the batch-specific COA, purity data, identity testing, lot number consistency, product form, storage information, and supplier language. The review should focus on procurement documentation, not personal-use expectations or product-use outcomes.
Why does a COA matter when buying PNC-27?
A PNC-27 COA matters because it links a specific batch to analytical documentation. Researchers should review the compound name, lot number, purity percentage, testing method, identity information, and product-form details. A COA supports procurement records but should be evaluated alongside labeling and supplier transparency.
Is PNC-27 intended for human or animal consumption?
PNC-27 discussed on this page is a research-use-only laboratory material and is not intended for human or animal consumption. Procurement review should not include personal-use, animal-use, clinical-use, diagnostic-use, therapeutic-use, or veterinary-use assumptions.
What does research use only mean for PNC-27?
Research use only means PNC-27 should be evaluated as a laboratory research material for controlled research settings. The designation directs attention to documentation, identity, purity, COA review, storage information, lot traceability, and supplier transparency rather than consumer use or clinical positioning.
How should published literature about PNC-27 be interpreted?
Published literature about PNC-27 should be interpreted as scientific context for research planning and documentation review. Structural, cell-model, ex vivo, or preclinical findings should not be treated as RUO product-use guidance, personal-use guidance, therapeutic guidance, or evidence of clinical suitability.
Next Steps
Qualified researchers evaluating PNC-27 should review product labeling, COA status, identity documentation, storage information, purity data, and supplier transparency before selecting any research-use-only material. Review the PNC-27 product page for RUO labeling, purity information, and available batch-specific documentation.
References
- U.S. Food and Drug Administration. “Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only.” FDA Guidance Document. 2013. fda.gov/regulatory-information/search-fda-guidance-documents/distribution-in-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only
- International Council for Harmonisation. “Q2(R2) Validation of Analytical Procedures.” ICH Guideline. 2023. database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130.pdf
- International Council for Harmonisation. “Q14 Analytical Procedure Development.” ICH Guideline. 2023. database.ich.org/sites/default/files/ICH_Q14_Guideline_2023_1116_1.pdf
- Sarafraz-Yazdi E, Mumin S, Cheung D, et al. “PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.” Biomedicines. 2022. mdpi.com/2227-9059/10/5/945
- The UniProt Consortium. “P04637 – Cellular tumor antigen p53 – Homo sapiens.” UniProtKB. 2026. uniprot.org/uniprotkb/P04637/entry
- The UniProt Consortium. “Q00987 – E3 ubiquitin-protein ligase Mdm2 – Homo sapiens.” UniProtKB. 2026. uniprot.org/uniprotkb/Q00987/entry
- Kussie PH, Gorina S, Marechal V, et al. “Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain.” Science. 1996. pubmed.ncbi.nlm.nih.gov/8875929
- Sarafraz-Yazdi E, Bowne WB, Adler V, et al. “Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.” Proceedings of the National Academy of Sciences. 2010. doi.org/10.1073/pnas.0909364107
- Mant CT, Hodges RS. “HPLC Analysis and Purification of Peptides.” Methods in Molecular Biology. 2007. pmc.ncbi.nlm.nih.gov/articles/PMC7119934
- Lian Z, Xu B, Wang W, et al. “Characterization of Synthetic Peptide Therapeutics Using Mass Spectrometry.” Journal of the American Society for Mass Spectrometry. 2021. doi.org/10.1021/jasms.0c00479
- United States Pharmacopeia. “<621> Chromatography.” USP Harmonized General Chapter. 2021. usp.org/sites/default/files/usp/document/harmonization/gen-chapter/harmonization-november-2021-m99380.pdf
- Prabhala BK, Addepalli B, Limbach PA. “Characterization of Synthetic Peptides by Mass Spectrometry.” Methods in Molecular Biology. 2015. pubmed.ncbi.nlm.nih.gov/26424265
- Mant CT, Hodges RS. “HPLC Analysis and Purification of Peptides.” PubMed. 2007. pubmed.ncbi.nlm.nih.gov/18604941
- Heitz F, Morris MC, Divita G. “Twenty years of cell-penetrating peptides.” British Journal of Pharmacology. 2009. pmc.ncbi.nlm.nih.gov/articles/PMC2697800
- Sookraj KA, Bowne WB, Adler V, Sarafraz-Yazdi E, Michl J, Pincus MR. “The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide.” Cancer Chemotherapy and Pharmacology. 2010. pubmed.ncbi.nlm.nih.gov/20182728
- Davitt K, Babcock BD, Fenelus M, et al. “The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.” Annals of Clinical and Laboratory Science. 2014. pubmed.ncbi.nlm.nih.gov/25117093
- Sarafraz-Yazdi E, Gorelick C, Wagreich AR, et al. “Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer.” Annals of Clinical and Laboratory Science. 2015. pubmed.ncbi.nlm.nih.gov/26663795
- Alagkiozidis I, Gorelick C, Shah T, et al. “Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer.” Annals of Clinical and Laboratory Science. 2017. pubmed.ncbi.nlm.nih.gov/28667027
- Rahmani R, Darroudi M, Gharanfoli M, Chamani J, Gholamin M, Hashemi M. “Conjugated PNC-27 peptide/PEI-Superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: In vitro study.” Iranian Journal of Basic Medical Sciences. 2022. doi.org/10.22038/IJBMS.2022.65590.14430
- Thadi A, Lewis L, Goldstein E, et al. “Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells.” Anticancer Research. 2020. doi.org/10.21873/anticanres.14488
- Pincus MR, Silberstein M, Zohar N, Sarafraz-Yazdi E, Bowne WB. “Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells.” Biomedicines. 2024. mdpi.com/2227-9059/12/6/1144
- Krzesaj P, Adler V, Feinman RD, Miller A, Silberstein M, Yazdi E, Pincus MR. “Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption.” Annals of Clinical and Laboratory Science. 2024. pubmed.ncbi.nlm.nih.gov/38802154
- Krzesaj PK, Seydafkan S, Miller AI, et al. “HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells.” Annals of Clinical and Laboratory Science. 2025. pubmed.ncbi.nlm.nih.gov/40750238
There are no reviews yet.